Literature DB >> 21844873

Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission.

W-C Chou, K-Y Peng, W-C Lei, B-S Ko, W Tsay, C-H Kuo, H-F Tien.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21844873     DOI： 10.1038/leu.2011.215

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 2.  Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia.

Authors:  Steven M Chan; Ravindra Majeti
Journal:  Int J Hematol       Date:  2013-08-15       Impact factor: 2.490

3.  Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype.

Authors:  Marijana Virijevic; Teodora Karan-Djurasevic; Irena Marjanovic; Natasa Tosic; Mirjana Mitrovic; Irena Djunic; Natasa Colovic; Ana Vidovic; Nada Suvajdzic-Vukovic; Dragica Tomin; Sonja Pavlovic
Journal:  Radiol Oncol       Date:  2016-09-08       Impact factor: 2.991

4.  Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.

Authors:  Chi Young Ok; Sanam Loghavi; Dawen Sui; Peng Wei; Rashmi Kanagal-Shamanna; C Cameron Yin; Zhuang Zuo; Mark J Routbort; Guilin Tang; Zhenya Tang; Jeffrey L Jorgensen; Rajyalakshmi Luthra; Farhad Ravandi; Hagop M Kantarjian; Courtney D DiNardo; L Jeffrey Medeiros; Sa A Wang; Keyur P Patel
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 11.047

Review 5.  Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?

Authors:  Daniela Cilloni; Jessica Petiti; Valentina Rosso; Giacomo Andreani; Matteo Dragani; Carmen Fava; Giuseppe Saglio
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

Review 6.  Strategies for minimal residual disease detection: current perspectives.

Authors:  Giacomo Andreani; Daniela Cilloni
Journal:  Blood Lymphat Cancer       Date:  2019-02-12

Review 7.  Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.

Authors:  Yashar Mesbahi; Toby N Trahair; Richard B Lock; Patrick Connerty
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

8.  IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.

Authors:  Houria Debarri; Delphine Lebon; Christophe Roumier; Meyling Cheok; Alice Marceau-Renaut; Olivier Nibourel; Sandrine Geffroy; Nathalie Helevaut; Philippe Rousselot; Bérengère Gruson; Claude Gardin; Marie-Lorraine Chretien; Shéhérazade Sebda; Martin Figeac; Céline Berthon; Bruno Quesnel; Nicolas Boissel; Sylvie Castaigne; Hervé Dombret; Aline Renneville; Claude Preudhomme
Journal:  Oncotarget       Date:  2015-12-08

9.  Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Authors:  Yann Ferret; Nicolas Boissel; Nathalie Helevaut; Jordan Madic; Olivier Nibourel; Alice Marceau-Renaut; Maxime Bucci; Sandrine Geffroy; Karine Celli-Lebras; Sylvie Castaigne; Xavier Thomas; Christine Terré; Hervé Dombret; Claude Preudhomme; Aline Renneville
Journal:  Haematologica       Date:  2018-02-22       Impact factor: 11.047

10.  IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics.

Authors:  Yasser H ElNahass; Ragia H Badawy; Fatma A ElRefaey; Hend A Nooh; Dalia Ibrahiem; Heba A Nader; Hossam K Mahmoud; Wafaa H ElMetnawy
Journal:  Asian Pac J Cancer Prev       Date:  2020-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.